BCTX

Briacell Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 0/10
  • Momentum↓ 0/10
Briacell Therapeutics sales and earnings growth
BCTX Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 70.42%
  • FCF Y/Y↓ -20.84%
Briacell Therapeutics gross and profit margin trends
BCTX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -911.50%
Briacell Therapeutics net debt vs free cash flow
BCTX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -283.9

Briacell Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗